Skip to content

J Affect Disord

ISSN 0165-0327; 1573-2517;

9 papers in the library · 143 citations · publishing 2018-2026

Papers

Natural speech algorithm applied to baseline interview data can predict which patients will respond to psilocybin for treatment-resistant depression.

J Affect Disord April 1, 2018 Facundo Carrillo, Mariano Sigman, Diego Fernández Slezak et al. 57 citations

An algorithm analyzing natural speech from baseline interviews can predict which patients with treatment-resistant depression will respond to psilocybin therapy. The approach uses vocal patterns and linguistic features to forecast treatment outcomes, suggesting that speech biomarkers may enable personalized medicine in mental health. This predictive capability could help identify likely responders before treatment begins, advancing precision psychiatry for depression.

DOI: 10.1016/j.jad.2018.01.006 Psychedelic therapy Psilocybin therapy Psilocybin treatment Depression treatment +17

Predicting the outcome of psilocybin treatment for depression from baseline fMRI functional connectivity.

J Affect Disord February 27, 2024 Debora Copa, David Erritzøe, Bruna Giribaldi et al. 31 citations

Brain connectivity patterns measured before psilocybin treatment can predict how much depression symptoms will improve. In people with treatment-resistant depression given two doses of psilocybin (25 mg each, one week apart), baseline resting-state functional MRI scans showed that connectivity within visual, default mode, and executive networks predicted early symptom improvement, while salience network connectivity predicted who would respond up to 24 weeks later, with about 90% accuracy. Similar patterns appeared in a separate trial comparing psilocybin to escitalopram. Fronto-occipital and fronto-temporal connections predicted early and late symptom reduction, respectively. Small sample sizes and differences between datasets limit generalizability, and the lack of a placebo arm limits specificity.

DOI: 10.1016/j.jad.2024.02.089 Psychedelic therapy Psychedelic-assisted therapy Psilocybin therapy Psilocybin treatment +16

Virtual mindfulness interventions to promote well-being in adults: A mixed-methods systematic review.

J Affect Disord January 4, 2022 Joy Xu, Helen Jo, Leena Noorbhai et al. 30 citations

A systematic review of virtual mindfulness-based interventions for adults aged 19 to 40 in developed countries found that practices such as basic mindfulness, Mindfulness-Based Stress Reduction (MBSR), Mindfulness-Based Cognitive Therapy (MBCT), and the Learning 2 BREATHE (L2B) program generally improved well-being. The review, which followed PRISMA guidelines and used a mixed-methods approach, analyzed heterogeneous studies qualitatively due to diverse designs. Modified versions of these interventions can be delivered virtually, offering an accessible way for adults to enhance their well-being.

DOI: 10.1016/j.jad.2022.01.027 Full text Digital mindfulness. Mental health. Stress reduction. Research review.

Subtypes of the psychedelic experience have reproducible and predictable effects on depression and anxiety symptoms.

J Affect Disord December 27, 2022 Aki Nikolaidis, Rafaelle Lancelotta, Natalie Gukasyan et al. 24 citations

Three reproducible subtypes of psychedelic experience were identified in a large sample of 985 people using machine learning. Subtypes differed in baseline demographics, mental health measures, and drug type and dose. Experiences linked to enduring improvements in anxiety, depression, and psychological wellbeing were characterized by greater personal and mystical insight. The subtypes were consistent across multiple psychedelic substances. Findings suggest that fostering insight experiences may be key to maximizing clinical benefits.

DOI: 10.1016/j.jad.2022.12.042 Full text Psychedelic-assisted therapy Psychedelic experiences Psychedelic journeys Hallucinogenic experiences +20

Interdisciplinary, Delphi-driven consensus guidelines on the use of intravenous ketamine infusions for depressive disorders from the American Society of Ketamine Physicians, Psychotherapists, and Practitioners (ASKP3).

J Affect Disord May 16, 2026 David S. Mathai, Madeleine Cluck, Amna M. Aslam et al. 1 citation

A panel of experts from the American Society of Ketamine Physicians, Psychotherapists, and Practitioners used a Delphi process to develop consensus guidelines for administering intravenous ketamine infusions to treat depressive disorders. The guidelines provide recommendations on patient selection, dosing, safety monitoring, and treatment protocols, aiming to standardize clinical practice and improve patient outcomes. The consensus reflects agreement among specialists on best practices for this off-label use of ketamine.

DOI: 10.1016/j.jad.2026.121970

Changes in depression symptom network structure following ketamine treatment in treatment-resistant depression.

J Affect Disord May 14, 2026 Joshua Curtiss, Laya Dasari, Julianne Origlio et al.

Patients with treatment-resistant depression whose symptoms are loosely connected before ketamine therapy are more likely to respond than those with tightly linked symptoms. Among 447 patients receiving intravenous ketamine or intranasal eskatamine, non-responders had denser pre-treatment symptom networks (global strength 4.03) compared with responders (global strength 1.06). After treatment, responders' network strength increased, while non-responders' decreased. Sparse baseline symptom networks may indicate greater capacity for reorganization, making pre-treatment network density a potential marker of ketamine response.

DOI: 10.1016/j.jad.2026.121964

Multiple peripheral inflammatory markers in adolescents with major depressive disorder treated with repeated esketamine infusions: results from a randomized controlled trial.

J Affect Disord February 23, 2026 Xiaofeng Lan, Zitao Wu, Chengyu Wang et al.

In a randomized controlled trial, adolescents with major depressive disorder who received repeated esketamine infusions showed changes in multiple peripheral inflammatory markers compared to those who received a placebo. The treatment was associated with reductions in certain inflammatory markers, suggesting that esketamine may influence immune system activity in this population. The findings indicate a potential link between the antidepressant effects of esketamine and its impact on inflammation, though the exact relationship requires further investigation.

DOI: 10.1016/j.jad.2026.121488